# A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

> **NCT06079320** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 16 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **DRUG:** Sisunatovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06079320
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-08
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study.
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079320, "A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06079320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*